---
title: "GRANDPHARMA subsidiary spends 316 million RMB to acquire an amino acid product company"
description: "GRANDPHARMA announced that its subsidiary Hubei GRANDPHARMA has signed a share purchase agreement to acquire 100% equity of Hebei GRANDPHARMA Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271193496.md"
published_at: "2025-12-31T08:50:12.000Z"
---

# GRANDPHARMA subsidiary spends 316 million RMB to acquire an amino acid product company

> GRANDPHARMA announced that its subsidiary Hubei GRANDPHARMA has signed a share purchase agreement to acquire 100% equity of Hebei GRANDPHARMA Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for RMB 316 million. These two companies focus on the production and sales of amino acids and thiol products. This acquisition will enhance the company's ability to integrate its industrial chain and promote its market expansion in the nutrition and daily chemical fields

GRANDPHARMA (00512.HK) announced that its subsidiary Hubei GRANDPHARMA has entered into a share purchase agreement to acquire all equity of Hebei GRANDPHARMA Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd., with a total consideration of RMB 316 million; the two companies are engaged in the production and sales of amino acid and thiol products, respectively. One of the sellers is China GRANDPHARMA, a shareholder of GRANDPHARMA.

The company stated that the target companies possess a complete industrial chain from amino acid raw materials to end health products, with significant cost advantages, leveraging the existing mature customer base to continuously explore market pipelines in human nutrition, animal nutrition, and personal care and daily chemical fields, implementing a "diversification development strategy."

### Related Stocks

- [00512.HK - GRANDPHARMA](https://longbridge.com/en/quote/00512.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/en/news/276886600.md) |
| San Miguel Brewery Hong Kong Swings Back to Profit in 2025 | San Miguel Brewery Hong Kong Limited reported a net profit of HK$78.4 million for the year ended December 31, 2025, a tu | [Link](https://longbridge.com/en/news/276914035.md) |
| 08:53 ETTransMedia Group to Uplift Mental Health & Addiction Advocacy of TV Personality and Upcoming Author Jennifer Gaydos Hartman | TransMedia Group is set to amplify the advocacy of Jennifer Gaydos Hartman, a TV personality and author, as mental healt | [Link](https://longbridge.com/en/news/276744925.md) |
| Tallgrass and Bridger Pipeline Announce a Joint Open Season from the Bakken for the Bridger and Pony Express Pipelines | Tallgrass and Bridger Pipeline have announced a joint open season for incentive tariff rates for crude oil transportatio | [Link](https://longbridge.com/en/news/276822877.md) |
| 08:49 ETTim Laros Launches ABC 360 | Tim Laros announces the launch of ABC 360, a science-informed nutrition bar designed to support sustained energy, recove | [Link](https://longbridge.com/en/news/276897407.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.